



**Universiteit  
Leiden**  
The Netherlands

## **Optimizing antifungal treatment through pharmacometrics: dosing considerations to enhance outcome**

Chen, L.

### **Citation**

Chen, L. (2023, December 19). *Optimizing antifungal treatment through pharmacometrics: dosing considerations to enhance outcome*. Retrieved from <https://hdl.handle.net/1887/3674169>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3674169>

**Note:** To cite this publication please use the final published version (if applicable).

**Optimizing antifungal treatment  
through pharmacometrics:  
dosing considerations to  
enhance outcome**

Printing of this thesis was financially supported by Certara

*Cover design:* Lu Chen and DALL·E 2

*Thesis lay-out:* Lu Chen

*Printing:* Ridderprint BV

© Copyright, Lu Chen, 2023

ISBN: 978-94-6483-565-6

All rights reserved. No part of this book may be reproduced in any form or by any means without permission of the author.

# Optimizing antifungal treatment through pharmacometrics: dosing considerations to enhance outcome

## Proefschrift

ter verkrijging van de graad van doctor aan de Universiteit Leiden,  
op gezag van rector magnificus prof.dr.ir. H. Bijl,  
volgens besluit van het college voor promoties  
te verdedigen op dinsdag 19 december 2023  
klokke 12.30 uur

door

Lu Chen

geboren te Yan'an, China

in 1993

**Promotor:**

Prof. dr. C.A.J. Knibbe

**Co-promotores:**

Dr. E.H.J. Krekels

Dr. R.J. Brüggemann (Radboudumc)

**Promotiecommissie:**

Prof. dr. H. Irth

Prof. dr. E.C.M. de Lange

Dr. E.M. Svensson (Uppsala University)

Dr. J.G.C. van Hasselt

Prof. dr. P.E. Verweij (Radboudumc)

The research described in this thesis was performed at the division Systems Pharmacology and Pharmacy of the Leiden Academic Centre for Drug Research (LACDR), Leiden University (Leiden, The Netherlands). The research was financially supported by the China Scholarship Council (CSC).

## Contents

<b>Section I</b>	<b>Background and introduction</b>	
<b>Chapter 1</b>	General introduction and scope	7
<b>Chapter 2</b>	Pharmacokinetics and Pharmacodynamics of Posaconazole	17
<b>Section II</b>	<b>Difference in posaconazole pharmacokinetics: formulation and population</b>	
<b>Chapter 3</b>	An integrated population pharmacokinetic analysis for posaconazole oral suspension, delayed-release tablet, and intravenous infusion in healthy volunteers	53
<b>Chapter 4</b>	Meta-PK analysis of posaconazole upon dosing of oral suspension, delayed-release tablet, and intravenous infusion in patients versus healthy volunteers: impact of clinical characteristics and race	75
<b>Section III</b>	<b>Fluconazole dose advice in obese adults</b>	
<b>Chapter 5</b>	Total bodyweight and sex both drive pharmacokinetic variability of fluconazole in obese adults	97
<b>Chapter 6</b>	Summary, lessons learned, perspectives, and overall conclusions	119
	Nederlandse samenvatting	133
<b>Appendices</b>	List of publications	136
	Curriculum vitae	137
	Acknowledgments	138